Recent Acquisition Expansion The acquisition of ImCheck Therapeutics by Ipsen Group for up to 1 billion euros underscores significant industry validation and increased market reach, providing a strong foundation for cross-selling immunotherapy solutions and expanding sales opportunities within top-tier pharmaceutical clients.

Advanced Clinical Pipeline ImCheck’s lead asset ICT01, which has received EMA Orphan Drug Designation and demonstrated promising interim results in AML trials, presents a compelling opportunity for partnerships and licensing agreements with specialty healthcare providers aiming to address unmet needs in oncology and autoimmune diseases.

Innovative Immunomodulation Focused on developing first-in-class antibodies targeting butyrophilins that modulate both innate and adaptive immunity, ImCheck offers cutting-edge therapeutic approaches that can appeal to research institutions and biotech companies seeking novel immunotherapy platforms.

Strategic Collaborations Supported by leading research institutions like INSERM and CNRS, as well as involvement in notable industry events like ASCO, ImCheck’s collaborations and visibility support opportunities to co-develop or co-market innovative therapies tailored to oncology and immune-related conditions.

Growing Financial Assets With funding of $22 million and revenue up to $10 million, ImCheck’s financial position signals potential for scaling sales efforts, especially in securing contracts with biotech or pharma partners focused on autoimmune and cancer immunotherapies.